期刊文献+

复方槲皮素乳膏治疗白癜风临床评价 被引量:4

Clinical Effect of Compound Quercetin Ointment in Treating Leukoderma
下载PDF
导出
摘要 目的观察复方槲皮素乳膏治疗白癜风的临床疗效及安全性。方法将医院皮肤科门诊诊治的76例白癜风患者随机分为3组,治疗组(A组)36例,病变局部外用复方槲皮素乳膏;对照1组(B组)20例,病变局部外用复方甲氧沙林乳膏;对照2组(C组)20例,病变局部外用0.1%他克莫司软膏。结果 3组总有效率分别为72.22%,44.44%和75.00%,A组、C组均明显优于B组(P<0.05);3组不良反应发生率分别为5.56%,60.00%和25.00%,A组、C组明显低于B组(P<0.01),且A组明显低于C组(P<0.05)。结论复方槲皮素乳膏与0.1%他克莫司软膏外涂治疗白癜风疗效相当,较复方甲氧沙林乳膏疗效显著,且不良反应少,值得临床推广。 Objective To observe the clinical effect and safety of Compound Quercetin Ointment in treating leukoderma. Methods Totally 76 patients with leukoderma in our hospital were divided into 3 groups,the group A (36 cases) was given Compound Quercetin Oint- ment,the control group l(group B,20 cases) was given Compound Methoxsalen Ointment,and the control group 2(group C,20 cases) was given 0. 1% Compound Tacrolimus Ointment. Results The total effective rates of 3 group were 72.22% ,44.44% ,75.00%, respectively,the group A and group C are obviously better than group B( P 〈 0. 05). The incidence rates of adverse reaction in the 3 groups were 5.56% ,60. 00% ,25.00% ,respectively,the group A and group C were obviously lower than group B(P 〈 0. 01), and the the group A were obviously lower than group C (P 〈 0. 05). Conclusion Compound Quercetin Ointment and 0.1% Compound Tacrolimus Ointment in treating leukoderma has similar effect,which is more effective than Compound Methoxsalen Ointment,it has less adverse reactions and worthy of clinical promotion.
作者 胡丽敏 孙绍伟 王滨 于鹏飞 魏传梅 Hu Limin Sun Shaowei Wang Bin Yu Pengfei Wei Chuanmei(Department of Pharmaceutical, The Affiliated Hospital of Binzhou Medical University, Binzhou, Shandong, China 25660)
出处 《中国药业》 CAS 2017年第10期45-47,共3页 China Pharmaceuticals
基金 山东省滨州市科技发展计划项目[2013ZC1801]
关键词 复方槲皮素乳膏 复方甲氧沙林乳膏 他克莫司软膏 白癜风 临床疗效 安全性 Compound Quercetin Ointment Methoxsalen Compound Ointment Tacrolimus Ointment leukoderma clinical effects safety
  • 相关文献

参考文献3

二级参考文献35

  • 1许进军,何东初.槲皮素研究进展[J].实用预防医学,2006,13(4):1095-1097. 被引量:23
  • 2陈双璐.卡波姆在凝胶剂中的应用现状[J].天津药学,2007,19(4):68-71. 被引量:16
  • 3Ring J, Mohrenschlager M, Henkel V, et al. The US FDA 'black box' warning for topical calcineurin inhibitors: an ongoing controversy. Drug Saf, 2008, 31 (3): 185-198.
  • 4Beeker JC, Houben R, Vetter CS, et al. The carcinogenic potential of taerolimus ointment beyond immune suppression: a hypothesis creating ease report. BMC Cancer, 2006, 6: 7.
  • 5Mattsson U, Magnusson B, Jontell M. Squamous cell carcinoma in a patient with oral lichen planus treated with topical application of tacrolimus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2010, 110(1 ): e19-e25.
  • 6yon Felbert V, Hampl M, Talhari C, et al. Squamous cell carcinoma arising from a localized vulval lesion of Hailey-Hailey disease after tacrolimus therapy. Am J Obstet Gyneeol, 2010, 203 (3): e5-e7.
  • 7Mikhail M, Wolchok J, Goldberg SM, et al. Rapid enlargement of a malignant melanoma in a child with vitiligo vulgaris after application of topical tacrolimus. Arch Dermatol, 2008, 144(4): 560-561.
  • 8Niwa Y, Terashima T, Sumi H. Topical application of the t tacrolimus accelerates carcinogenesis in mouse skin. Br J Dermatol, 2003, 149(5): 960-967.
  • 9Tennis P, Gelfand JM, Rothman KJ. Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors. Br J Dermatol, 2011, 165(3): 465-473.
  • 10Kimata H. Kapos's varicelliform eruption associated with the use of tacrolimus ointment in two neonates. Indian J Dermatol Venereol Leprol, 2008, 74 (3): 262-263.

共引文献805

同被引文献45

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部